Today: 7 February 2026
Subscribe
Browse Category

NYSE:SAIL News 14 December 2025 - 4 January 2026

SailPoint stock slides 6% into 2026 — here’s what investors watch before Monday

SailPoint stock slides 6% into 2026 — here’s what investors watch before Monday

NEW YORK, Jan 4, 2026, 12:44 ET — Market closed SailPoint, Inc. shares ended Friday down 6.3% at $18.95, setting the identity-security firm’s stock up for a closely watched Monday open after a late-week slide. SailPoint Investor The drop matters now because software stocks that trade on future growth tend to swing with interest-rate expectations, and investors face a packed U.S. data calendar in the first full week of 2026. Those releases can quickly shift bond yields — and, by extension, equity valuations. Bureau of Labor Statistics Federal Reserve Bank of Philadelphia President Anna Paulson said policymakers may wait before
4 January 2026
·
SailPoint stock tumbles 6% to start 2026 as SAIL traders brace for next catalysts

SailPoint stock tumbles 6% to start 2026 as SAIL traders brace for next catalysts

NEW YORK, Jan 3, 2026, 20:51 ET — Market closed SailPoint, Inc. shares fell 6.3% on Friday, ending the session at $18.95 and giving the identity-security software maker one of its sharpest daily drops in recent weeks, according to Investing.com market data. The move mattered because investors opened 2026 with an uneven appetite for growth, even as the Dow finished higher and the Nasdaq ended roughly flat, a Reuters market report showed. That backdrop tends to amplify swings in recently listed software names that trade on expectations of future subscription growth, rather than near-term profits. SailPoint also sits in a
4 January 2026
·
SailPoint stock sinks 6% today: what’s driving SAIL and what to watch next

SailPoint stock sinks 6% today: what’s driving SAIL and what to watch next

NEW YORK, Jan 2, 2026, 15:10 ET — Regular session Shares of SailPoint, Inc. fell about 6.5% on Friday, giving the identity security software maker one of the sharpest declines among mid-cap cybersecurity stocks. The drop matters because investors are opening the new year reassessing risk after 2025’s strong run, with attention shifting back to valuations and the interest-rate outlook that tends to drive high-growth software. Reuters “Stocks trade expensive on 18 of 20 measures,” said Savita Subramanian, Bank of America’s equity and quant strategist, in a note, as investors looked ahead to next week’s labor-market data for clues on
2 January 2026
·
Cybersecurity US Stocks Week Ahead (Dec. 15–19, 2025): Zscaler’s Bounce Test, SailPoint’s Post-Earnings Reset, and Fed-Cut Volatility

Cybersecurity US Stocks Week Ahead (Dec. 15–19, 2025): Zscaler’s Bounce Test, SailPoint’s Post-Earnings Reset, and Fed-Cut Volatility

Updated Sunday, December 14, 2025 (market data through the Dec. 12 close). US cybersecurity stocks head into the new week after a volatile stretch that mixed a dovish Federal Reserve rate cut with a sudden risk-off pulse in megacap tech—an uncomfortable combination for a sector that often trades like “defensive growth.” The result: investors are still rewarding high-quality recurring revenue and platform narratives, but they’re also getting more selective on valuation, guidance tone, and “AI spending” second-order effects. Below is what moved major US-listed cybersecurity names between Dec. 8–14, 2025, and what to watch next week across CrowdStrike (CRWD), Palo
14 December 2025
···········

Stock Market Today

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop